<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1106233779
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2018
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        TANDO 20 mg Film Coted Tablet
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        TADALAFIL
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        4
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        48
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        64.85
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="SAJA-SAUDI ARABIAN JAPANESE PHARMACEUTICAL CO" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            SAJA-SAUDI ARABIAN JAPANESE PHARMACEUTICAL CO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 360]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Farouk, Maamoun Tamer & CO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            SAJA-SAUDI ARABIAN JAPANESE PHARMACEUTICAL CO
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        G04BE08
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Tando&reg; is a treatment for adult men with erectile dysfunction. This is when a man cannot get, or keep a hard, erect penis suitable for sexual activity. Tando&reg; has been shown to significantly improve the ability of obtaining a hard erect penis suitable for sexual activity.</p><p>Tando&reg; contains the active substance tadalafil which belongs to a group of medicines called phosphodiesterase type 5 inhibitors. Following sexual stimulation Tando&reg; works by helping the blood vessels in your penis to relax, allowing the flow of blood into your penis. The result of this is improved erectile function. Tando&reg; will not help you if you do not have erectile dysfunction.</p><p>It is important to note that Tando&reg; does not work if there is no sexual stimulation. You and your partner will need to engage in foreplay, just as you would if you were not taking a medicine for erectile dysfunction.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Tando&reg; if you:</strong></p><p>- are allergic to tadalafil or any of the other ingredients of this medicine (listed in section 7).</p><p>- are taking any form of organic nitrate or nitric oxide donors such as amyl nitrite. This is a group of medicines (&ldquo;nitrates&rdquo;) used in the treatment of angina pectoris (&ldquo;chest pain&rdquo;). Tando&reg; has been shown to increase the effects of these medicines. If you are taking any form of nitrate or are unsure tell your doctor.</p><p>- have serious heart disease or recently had a heart attack within the last 90 days.</p><p>- Recently had a stroke within the last 6 months.</p><p>- have low blood pressure or uncontrolled high blood pressure.</p><p>- Ever had loss of vision because of non-arteritic anterior ischemic optic neuropathy (NAION), a condition described as &ldquo;stroke of the eye&rdquo;.</p><p>- are taking riociguat. This drug is used to treat pulmonary arterial hypertension (i.e., high blood pressure in the lungs) and chronic thromboembolic pulmonary hypertension (i.e., high blood pressure in the lungs secondary to blood clots). PDE5 inhibitors, such as Tando&reg;, have been shown to increase the hypotensive effects of this medicine. If you are taking riociguat or are unsure tell your doctor.</p><p><strong>Warnings and precautions</strong></p><p>Talk to your doctor before taking Tando&reg;.</p><p>Be aware that sexual activity carries a possible risk to patients with heart disease because it puts an extra strain on your heart. If you have a heart problem you should tell your doctor.</p><p>Before taking the tablets, tell your doctor if you have:</p><p>- Sickle cell anaemia (an abnormality of red blood cells).</p><p>- Multiple myeloma (cancer of the bone marrow).</p><p>- Leukemia (cancer of the blood cells).</p><p>- Any deformation of your penis.</p><p>- A serious liver problem.</p><p>- A severe kidney problem.</p><p>It is not known if Tando&reg; is effective in patients who have had:</p><p>- Pelvic surgery.</p><p>- Removal of all or part of the prostate gland in which nerves of the prostate are cut (radical nonnerve sparing prostatectomy).</p><p>If you experience sudden decrease or loss of vision, stop taking Tando&reg; and contact your doctor immediately.</p><p>Tando&reg; is not intended for use by women.</p><p><strong>Children and adolescents</strong></p><p>Tando&reg; is not intended for use by children and adolescents under the age of 18.</p><p><strong>Other medicines and Tando&reg;</strong></p><p>Tell your doctor if you are taking, have recently taken or might take any other medicines</p><p>Do not take Tando&reg; if you are already taking nitrates.</p><p>Some medicines may be affected by Tando&reg; or they may affect how well Tando&reg; will work. Tell your doctor or pharmacist if you are already taking:</p><p>- An alpha blocker (used to treat high blood pressure or urinary symptoms associated with benign</p><p>prostatic hyperplasia).</p><p>- Other medicines to treat high blood pressure.</p><p>- riociguat.</p><p>- A -5 alpha reductase inhibitor (used to treat benign prostatic hyperplasia).</p><p>- Medicines such as ketoconazole tablets (to treat fungal infections) and protease inhibitors for</p><p>treatment of AIDS or HIV infection.</p><p>- Phenobarbital, phenytoin and carbamazepine (anticonvulsant medicines).</p><p>- Rifampicin, erythromycin, clarithromycin or itraconazole.</p><p>- Other treatments for erectile dysfunction.</p><p><strong>Tando&reg; with drink and alcohol</strong></p><p>Information on the effect of alcohol is in section 3. Grapefruit juice may affect how well Tando&reg; will</p><p>work and should be taken with caution. Talk to your doctor for further information.</p><p>Fertility</p><p>When dogs were treated there was reduced sperm development in the testes. A reduction in sperm</p><p>was seen in some men. These effects are unlikely to lead to a lack of fertility.</p><p><strong>Driving and using machines</strong></p><p>Some men taking Tando&reg; in clinical studies have reported dizziness. Check carefully how you react to the tablets before driving or using machines.</p><p><strong>Tando&reg; contains lactose:</strong></p><p>If you have an intolerance to some sugars, contact your doctor before taking this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist</p><p>if you are not sure.</p><p>Tando&reg; tablets are for oral use in men only. Swallow the tablet whole with some water. The tablets</p><p>can be taken with or without food.</p><p>The recommended starting dose is one 10 mg tablet before sexual activity. However, you have been</p><p>given the dose of one 20mg tablet as your doctor has decided that the recommended dose of 10mg</p><p>is too weak.</p><p>You may take a Tando&reg; tablet at least 30 minutes before sexual activity.</p><p>Tando&reg; may still be effective up to 36 hours after taking the tablet.</p><p>Do not take Tando&reg; more than once a day. Tando&reg; 10 mg and 20 mg is intended for use prior to</p><p>anticipated sexual activity and is not recommended for continuous daily use.</p><p>It is important to note that Tando&reg; does not work if there is no sexual stimulation. You and your partner will need to engage in foreplay, just as you would if you were not taking a medicine for erectile dysfunction.</p><p>Drinking alcohol may affect your ability to get an erection and may temporarily lower your blood</p><p>pressure. If you have taken or are planning to take Tando&reg;, avoid excessive drinking (blood alcohol level</p><p>of 0.08 % or greater), since this may increase the risk of dizziness when standing up. If you take more</p><p>Tando&reg; than you should</p><p>Contact your doctor. You may experience side effects described in section 5.</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. These effects are normally mild to moderate in nature.</p><p>If you experience any of the following side effects stop using the medicine and seek medical help immediately:</p><p>- Allergic reactions including rashes (frequency uncommon).</p><p>- Chest pain - do not use nitrates but seek immediate medical assistance (frequency uncommon).</p><p>- Prolonged and possibly painful erection after taking Tando&reg; (frequency rare). If you have such an erection, which lasts continuously for more than 4 hours you should contact a doctor immediately.</p><p>- Sudden loss of vision (frequency rare).</p><p>Other side effects have been reported:</p><p>Common (seen in 1 to 10 in every 100 patients)</p><p>- Headache, back pain, muscle aches, pain in arms and legs, facial flushing, nasal congestion, and</p><p>indigestion.</p><p>Uncommon (seen in 1 to 10 in every 1,000 patients)</p><p>- dizziness, stomach ache, feeling sick, being sick (vomiting), reflux, blurred vision, eye pain, difficulty in breathing, presence of blood in urine, pounding heartbeat sensation, a fast heart rate, high blood pressure, low blood pressure, nose bleeds, ringing in the ears, swelling of the hands, feet or ankles and feeling tired.</p><p>Rare (seen in 1 to 10 in every 10,000 patients)</p><p>- fainting, seizures and passing memory loss, swelling of the eyelids, red eyes, sudden decrease or loss of hearing, hives (itchy red welts on the surface of the skin), penile bleeding, presence of blood in semen and increased sweating.</p><p>Heart attack and stroke have also been reported rarely in men taking Tando&reg;. Most of these men had known heart problems before taking this medicine.</p><p>Partial, temporary, or permanent decrease or loss of vision in one or both eyes has been rarely reported.</p><p>Some additional rare side effects have been reported in men taking Tando&reg; that were not seen in clinical trials. These include:</p><p>- migraine, swelling of the face, serious allergic reaction which causes swelling of the face or throat,</p><p>serious skin rashes, some disorders affecting blood flow to the eyes, irregular heartbeats, angina and sudden cardiac death.</p><p>The side effect dizziness has been reported more frequently in men over 75 years of age taking Tando&reg;.</p><p>Diarrhea has been reported more frequently in men over 65 years of age taking Tando&reg;.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&bull; Store below 30 C</p><p>&bull; Keep this medicine out of the sight and reach of children.</p><p>&bull; Do not use this medicine after the expiry date which is stated on the carton and on each blister after EXP. The expiry date refers to the last day of that month.</p><p>This medicine does not require any special storage conditions.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is Tadalafil. Each film coated tablet contains 20 mg of tadalafil.</p><p>The other ingredients are:</p><p>Lactose Monohydrate, Low Substituted Hydroxypropyl Cellulose, Croscarmellose Sodium, Sodium</p><p>Lauryl Sulfate, Microcrystalline Cellulose, Magnesium stearate and Opadry Yellow 02A22352.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Buff, Oblong, biconvex film coated tablets imposed with SJ521 in one side
Tando® is provided in a pack containing one blister (ALU/ALU blister) of 4 film coated tablets.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>SAJA Pharmaceuticals</p><p>Saudi Arabian Japanese pharmaceutical company limited</p><p>Jeddah &ndash; Saudi Arabia</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                November/2016
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يُستخدم تاندو 20 ملج لعلاج الرجال البالغين المصابين بالتَّالي:</p><p dir="RTL">- الاضطرابات بالانتصاب. وهي حالة لا يستطيع الرَّجل فيها الحصول أو الحفاظ على عضو ذكري منتصب وصلب بشكل مناسب؛ للممارسة الجماع. ثبت أن تاندو يحسن بشكل ملحوظ من القدرة على الحصول على عضو ذكري منتصب وصلب بشكل مناسب لممارسة الجماع.</p><p dir="RTL">بعد الإثارة الجنسية، يعمل تاندو من خلال مساعدة الأوعية الدَّموية في العضو الذكري لديك على الاسترخاء، مما يسمح بتدفق الدَّم إليه. ينتج عن ذلك تحسن القدرة على الانتصاب.</p><p dir="RTL">لن يُساعدك تاندو إذا لم تكن تعاني من اضطرابات بالانتصاب. من المهم ملاحظة التَّالي:</p><p dir="RTL">لا يعمل تاندو المستخدم لعلاج الاضطرابات بالانتصاب في حال عدم وجود إثارة جنسية.</p><p dir="RTL">يتعين عليك وعلى شريكتك في الجماع الانخراط في المداعبة، كما قد تفعلان بالضبط إذا لم تكن تتناول دواءً لعلاج اضطرابات الانتصاب.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تتناول تاندو في الحالات التَّالية:</strong></p><p dir="RTL">- إذا كنت تعاني من حساسية تجاه تادالافيل أو أيٍّ من المكونات الأخرى بهذا الدَّواء (المدرجة في قسم:7).</p><p dir="RTL">- إذا كنت تتناول أي شكل من أشكال النترات العضوية أو المواد التي تمد الجسم بحمض أكسيد النتريك مثل: نترات الأميل. هذه فئة من الأدوية (&quot;النترات&quot;) التي تُستخدم في علاج الذبحة الصدرية (&quot;ألم الصدر&quot;). ثبت أن تاندو يعزز تأثير هذه الأدوية. إذا كنت تتناول أي شكل من أشكال النترات أو إذا لم تكن متأكدًا من ذلك، فأخبر طبيبك.</p><p dir="RTL">- إذا كان لديك مرض خطير بالقلب أو إذا كنت قد أصبت مؤخرًا بنوبة قلبية في غضون الـ ٩٠ يومًا السابقة.</p><p dir="RTL">- إذا كنت قد أصبت بسكتة دماغية في غضون الستة أشهر الماضية.</p><p dir="RTL">- إذا كنت تعاني من انخفاض ضغط الدَّم أو من ارتفاع ضغط الدَّم غير المنضبط.</p><p dir="RTL">- إذا كنت قد فقدت بصرك من قبل بسبب اعتلال عصبي بصري إقفاري أمامي غير مرتبط بالشرايين، وهي حالة تسمى: &quot;سكتة العين&quot;.</p><p dir="RTL">- إذا كنت تتناول دواء ريوسيجوات. يُستخدم هذا الدَّواء لعلاج ارتفاع ضغط الدَّم بالشرايين الرئوية (على سبيل المثال: ارتفاع ضغط الدَّم في الرئتين) ولعلاج ارتفاع ضغط الدَّم الرئوي المزمن الانصمامي الخثاري (على سبيل المثال: ارتفاع ضغط الدَّم في الرئتين النَّاجم عن الجلطات الدَّموية). ثبت أن مثبطات ثنائي إستراز الفوسفات من النوع ٥ مثل تاندو تعزز التَّأثير الخافض لضغط الدَّم لهذا الدواء. إذا كنت تتناول دواء ريوسيجوات أو إذا لم تكن متأكدًا من ذلك، فأخبر طبيبك.</p><p dir="RTL"><strong>تحذيرات واحتياطات</strong></p><p dir="RTL">تحدَّث إلى طبيبك قبل تناول تاندو</p><p dir="RTL">انتبه إلى أن ممارسة الجماع تشكل خطرًا محتملاً للمرضى المصابين بأمراض القلب؛ نظرًا لأنها تجهد القلب لديك أكثر. إذا كان لديك مشكلة بالقلب، فأخبر طبيبك بها.</p><p dir="RTL">قبل تناوُل أقراص العقار، أخبر طبيبك إذا كنت تعاني من أي مما يلي:</p><p dir="RTL">- فقر الدَّم المنجلي (اضطراب في خلايا الدَّم الحمراء).</p><p dir="RTL">- الورم النقوي المتعدد (سرطان بالنخاع العظمي).</p><p dir="RTL">- سرطان الدَّم (سرطان في خلايا الدَّم).</p><p dir="RTL">- أي تشوهات بالعضو الذكري لديك.</p><p dir="RTL">- مشكلة خطيرة بالكبد.</p><p dir="RTL">- مشكلة خطيرة بالكلى.</p><p dir="RTL">من غير المعروف ما إذا كان تاندو فعالاً في المرضى ممن سبق قيامهم بالتَّالي:</p><p dir="RTL">- الخضوع لجراحة بالحوض.</p><p dir="RTL">- الخضوع لاستئصال جزء من غدة البروستاتا يتم فيه استئصال بعض أعصاب البروستاتا (استئصال بروستاتا جذري غير محصن للأعصاب) أو استئصالها كلية.</p><p dir="RTL">إذا عانيت من ضعف مفاجئ في الإبصار أو من فقدان بصر مفاجئ، توقف عن تناوُل تاندو، واتصل بطبيبك في الحال.</p><p dir="RTL">تاندو ليس معدًّا للاستخدام من قِبَل السيدات.</p><p dir="RTL"><strong>الأطفال والمراهقون:</strong></p><p dir="RTL">تاندو ليس معدًّا للاستخدام من قِبَل الأطفال والمراهقين الذين تقل أعمارهم عن ١٨ عامًا.</p><p dir="RTL"><strong>الأدوية الأخرى وتاندو</strong></p><p dir="RTL">يُرجى إبلاغ طبيبك إذا كنت تتناول أو تناولت مؤخرًا أو قد تتناول أيَّة أدوية أخرى.</p><p dir="RTL">لا تتناول تاندو إذا كنت تتناول بالفعل النترات.</p><p dir="RTL">قد تتأثر فعالية بعض الأدوية بتناوُل تاندو أو قد تُؤثر في فعالية تاندو أخبر طبيبك أو الصيدلي الخاص بك إذا كنت تتناول بالفعل أيًّا مما يلي:</p><p dir="RTL">- أحد حاصرات ألفا (تُستخدم لعلاج ارتفاع ضغط الدَّم أو أعراض التبول المصاحبة لفرط تنسج البروستاتا الحميد).</p><p dir="RTL">- أدوية أخرى لعلاج ارتفاع ضغط الدَّم.</p><p dir="RTL">- ريوسيجوات.</p><p dir="RTL">- مثبط مختزلة ألفا -٥ (يُستخدم لعلاج فرط تنسج البروستاتا الحميد).</p><p dir="RTL">- أدوية مثل: أقراص كيتوكونازول (تُستخدم لعلاج عدوى الفطريات) ومثبطات بروتياز لعلاج فيروس الإيدز أو فيروس نقص المناعة البشرية.</p><p dir="RTL">- فينوباربيتال، فينيتوين وكرْبامازِيبين (أدوية مضادة للاختلاجات).</p><p dir="RTL">- ريفامبيسين، أو إريثروميسين، أو كلاريثروميسين، أو أتراكونازول.</p><p dir="RTL">- علاجات أخرى للاضطرابات بالانتصاب.</p><p dir="RTL"><strong>تناوُل تاندو مع الأطعمة والمشروبات</strong></p><p dir="RTL">تتوفر المعلومات حول تأثير الكحوليات على العقار في القسم ٤. قد يُؤثر عصير الجريب فروت على الكفاءة التي سيعمل بها تاندو، من ثَم يجب تناوُله بحذر للحصول على مزيد من المعلومات، تحدَّث مع طبيبك.</p><p dir="RTL"><strong>الخصوبة</strong></p><p dir="RTL">عند علاج الكلاب بالعقار، انخفض تكون الحيوانات المنوية في الخصيتين. لُوحظ في بعض الرجال انخفاض عدد الحيوانات المنوية لديهم. من<br />المستبعد أن تؤدي هذه التأثيرات إلى نقص الخصوبة.</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">أبلغ بعض الرجال الذين تناولوا تاندو في الدراسات السريرية عن إصابتهم بالدوخة. يُرجى التََّحقق بعناية من استجابتك للأقراص قبل القيادة أو<br />استخدام الآلات.</p><p dir="RTL"><strong>يحتوي تاندو على اللاكتوز:</strong></p><p dir="RTL">من ثَم إن كنت لا تتحمل بعض أنواع السكريات، اتصل بطبيبك قبل تناوُل هذا الدَّواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">تناول دائمًا هذا الدَّواء كما أخبرك طبيبك بالضبط. يُرجى مراجعة الطبيب أو الصيدلي الخاص بك إذا لم تكن متأكدًا من كيفية تناوُله.</p><p dir="RTL">تاندو أقراص مخصص للاستخدام عن طريق الفم في الرجال فقط. ابتلع القرص كاملاً مع بعض الماء. يمكن تناوُل الأقراص مع الطعام أو بدونه.</p><p dir="RTL">الجرعة الموصي بها هي قرص واحد 10 ملج قبل ممارسة الجماع. إذا كان تأثير هذه الجرعة ضعيفة جدا طبيبك قد تزيد الجرعة إلى 20 ملج. أقراص تاندو هي للاستخدام عن طريق الفم.</p><p dir="RTL">يمكنك أن تأخذ قرص تاندو على الأقل 30 دقيقة قبل النشاط الجنسي.</p><p dir="RTL">قد يكون تاندو ما زال فعال إلى 36 ساعة بعد تناول قرص.</p><p dir="RTL">لا تأخذ تاندو أكثر من مرة في اليوم. تاندو 10 ملج و20 ملج للاستخدام قبل النشاط الجنسي وليس من المستحسن الاستخدام اليومي المستمر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يخفض تناوُل الكحوليات ضغط الدَّم لديك بشكل مؤقت. إذا كنت قد تناولت تاندو أو تخطط لتناوُله، تجنب الإفراط من شرب الكحوليات<br />(وصول مستوى الكحوليات بالدَّم إلى 0.08% أو أكثر؛ إذ إن هذا قد يرفع خطر الإصابة بدوخة عن الوقوف.</p><p dir="RTL">من المهم ملاحظة أن تاندو ليس فعالًا في حالة عدم وجود إثارة جنسية. يتعين عليك وعلى شريكتك في الجماع الانخراط في المداعبة، كما قد تفعلان بالضبط إذا لم تكن تتناول دواءً لعلاج اضطرابات الانتصاب.</p><p dir="RTL">قد يؤثر شرب الكحوليات على قدرتك على الحصول على انتصاب.</p><p dir="RTL">إذا تناولت كمية أكثر مما يجب من تاندو أقراص، فيجب عليك الاتصال بطبيبك. قد تواجه الآثار الجانبية الموضحة في القسم 5.</p><p dir="RTL">إذا أغفلت تناول تاندو أقراص</p><p dir="RTL">إذا كانت لديك أيه أسئلة إضافية حول استخدام هذا الدواء، فاستشر الطبيب أو الصيدلي الخاص بك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثله مثل كافة الأدوية، قد يُسبب هذا الدَّواء آثارًا جانبية، على الرغم من عدم حدوثها لدى الجميع. تكون هذه الآثار الجانبية عادةً بسيطة إلى<br />معتدلة في طبيعتها.</p><p dir="RTL">إذا كنت تعاني من أيٍّ من الآثار الجانبية التََّالية فتوقف عن تناوُل هذا الدَّواء، واطلب مساعدة طبية على الفور:</p><p dir="RTL">- تفاعلات حساسية بما في ذلك الطفح الجلدي (نسبة تكرار غير شائعة).</p><p dir="RTL">- ألم في الصدر- لا تستخدم النترات، لكن اطلب مساعدة طبية (نسبة تكرار غير شائعة).</p><p dir="RTL">- انتصاب لفترة طويلة قد يكون مؤلمًا بعد تناوُل تاندو (نسبة تكرار نادرة). إذا كنت تعاني من هذا الانتصاب الذي يستمر بلا انقطاع لأكثر من ٤ ساعات، يجب عليك الاتصال بطبيب في الحال.</p><p dir="RTL">- فقدان بصر مفاجئ (نسبة التكرار نادرة).</p><p dir="RTL">تم الإبلاغ عن آثار جانبية أخرى:</p><p dir="RTL">شائعة (تلاحظ في ١ من ١٠ في كل ١٠٠ مريض)</p><p dir="RTL">- صداع، آلام بالظهر، آلام بالعضلات، آلام بالذراعين والساقين، احمرار جلد الوجه، احتقان بالأنف وعسر هضم.</p><p dir="RTL">غير شائعة (تلاحظ في ١ من ١٠ في كل ١٠٠٠ مريض).</p><p dir="RTL">- دوخة، وألم بالبطن، وشعور بالإعياء، وإعياء (قيء)، وارتجاع، وعدم وضوح الرؤية، وألم بالعين، وصعوبة في التَّنفس، ووجود دم في البول، وشعور بخفقان ضربات القلب، وسرعة ضربات القلب، وارتفاع ضغط الدَّم، وانخفاض ضغط الدَّم، ونزيف من الأنف، وطنين بالأذنين، وتورم اليدين أو القدمين أو الكاحلين، والشعور بالتعب.</p><p dir="RTL">نادرة (تلاحظ في ١ من 10 في كل 10.000 مريض)</p><p dir="RTL">- إغماء، نوبات تشنجية، وفقدان ذاكرة عابر، وتورم الجفنين، واحمرار العينين، وضعف سمع مفاجئ أو فقدان سمع مفاجئ، وشرى (أرتكاريا) (انتبار أحمر مصحوب بحكة على سطح الجلد)، ونزيف بالعضو الذكري، ووجود دم في المني وزيادة التعرق.</p><p dir="RTL">تم الإبلاغ أيضًا بشكل نادر عن الإصابة بنوبة قلبية وسكتة دماغية في الرجال الذين يتناولون عقار تاندو. كان أغلب هؤلاء الرجال يعانون من مشاكل بالقلب قبل تناوُل هذا الدَّواء.</p><p dir="RTL">تم الإبلاغ بشكل نادر عن ضعف رؤية جزئي أو مؤقت أو دائم أو فقدان رؤية في عين واحدة أو في كلا العينين.</p><p dir="RTL">تم الإبلاغ عن بعض الآثار الجانبية الإضافية النَّادرة التي لم تُلاحظ في التجارب السريرية في الرجال الذين يتناولون تاندو.</p><p dir="RTL">تشمل هذه الآثار الجانبية:</p><p dir="RTL">- الصداع النصفي، وتورم الوجه، وتفاعلات حساسية خطيرة تُسبب تورم الوجه أو الحلق، أو طفح جلدي خطير، أو بعض الاضطرابات التي تُؤثر على تدفق الدَّم إلى العينين، وعدم انتظام ضربات القلب، والذبحة الصدرية، والموت المفاجئ بسبب نوبة قلبية.</p><p dir="RTL">تم الإبلاغ عن أثر جانبي هو الدوخة بشكل أكثر تكرارًا في الرجال الذين تزيد أعمارهم عن ٧٥ عامًا ممن يتناولون تاندو. تم الإبلاغ عن الإسهال بشكل أكثر تكرارًا في الرجال الذين تزيد أعمارهم عن ٦٥ عامًا ممن يتناولون تاندو.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يُحفَظ في درجة حرارة أقل من ٣٠ درجة مئوية.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يُحفظ هذا الدَّواء بعيدًا عن رؤية ومُتناوَل الأطفال.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تستعمل هذا الدواء بعد انتهاء الصلاحية المدون على العبوة وعلى كل شريط بعد كلمة &quot;EXP&quot;. يُشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من ذلك الشهر.</p><p dir="RTL">هذا الدواء لا يحتاج لظروف تخزين خاصة.</p><p dir="RTL">لا تتخلص من أي أدوية عن طريق إلقائها في مياه الصرف أو مع المخلفات المنزلية. استشر الصيدلي الخاص بك حول كيفية التخلص من الأدوية التي لم تَعُد تستخدمها. سوف تُساعد هذه الإجراءات في الحفاظ على البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">المادة الفعالة هي تادالافيل يحتوي كل قرص مغلف على 20 ملج من تادالافيل.</p><p dir="RTL">المكونات الأخرى هي:</p><p dir="RTL">اللاكتوز أحادي الهيدرات، هيدروكسي بروبيل السليلوز منخفض التركيز، كروسكارميلوز الصوديوم، صوديوم لوريل سلفات، سليلوز دقيق التبلور، ستيرات الماغنسيوم، وأوبادري أصفر 02A22352</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">أقراص بيضاوية ثنائية التَّحدب ذات لون أصفر برتقالي مائل الي البيج محفور SJ521 على أحد جانبيها.</p><p dir="RTL">يتوفر تاندو في عبوة تحتوى على شريط (ألمونيوم / ألمونيوم) به 4 أقراص مغلفة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">شركة ساجا الصيدلانية</p><p dir="RTL">الشركة السعودية اليابانية للمنتجات الصيدلانية، شركة محدودة</p><p dir="RTL">جدة - المملكة العربية السعودية</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            نوفمبر / 2016
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                TANDO® 5 mg, 10 mg and 20 mg film-coated tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each 5 mg tablet contains 5 mg tadalafil.
Excipient with known effect: lactose monohydrate.
Each 10 mg tablet contains 10 mg tadalafil.
Excipient with known effect: lactose monohydrate.
Each 20 mg tablet contains 20 mg tadalafil.
Excipient with known effect: lactose monohydrate.
For the full list of excipients, see section 6.1
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablet.
The 5 mg tablet are buff to beige round shaped biconvex F.C tablet with code SJ 752 in one side.
The 10 mg tablets are buff to beige round shaped biconvex F.C tablet with code SJ 522 in one
side.
The 20 mg tablets are buff to beige oval shaped biconvex F.C tablet with code SJ 521 in one
side
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Treatment of erectile dysfunction in adult males.<br />In order for tadalafil to be effective for the treatment of erectile dysfunction, sexual stimulation is<br />required.<br />5 mg only: Treatment of the signs and symptoms of benign prostatic hyperplasia in adult males.<br />TANDO&reg; is not indicated for use by women<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Posology<br />Erectile dysfunction in adult Men<br />In general, the recommended dose is 10 mg taken prior to anticipated sexual activity and with or<br />without food.<br />In those patients in whom tadalafil 10 mg does not produce an adequate effect, 20 mg might be<br />tried. It may be taken at least 30 minutes prior to sexual activity.<br />The maximum dose frequency is once per day.<br />Tadalafil 10 and 20 mg is intended for use prior to anticipated sexual activity and it is not<br />recommended for continuous daily use.<br />In patients who anticipate a frequent use of TANDO&reg; (i.e., at least twice weekly) a once daily<br />regimen with the lowest doses of TANDO&reg; might be considered suitable, based on patient choice<br />and the physician&#39;s judgement.<br />In these patients, the recommended dose is 5mg taken once a day at approximately the same<br />time of day. The dose may be decreased to 2.5mg once a day based on individual tolerability.<br />The appropriateness of continued use of the daily regimen should be reassessed periodically.<br />Benign prostatic hyperplasia in adult men (tadalafil 5 mg only)<br />The recommended dose is 5 mg, taken at approximately the same time every day with or without<br />food. For adult men being treated for both benign prostatic hyperplasia and erectile dysfunction<br />the recommended dose is also 5 mg taken at approximately the same time every day. Patients<br />who are unable to tolerate tadalafil 5 mg for the treatment of benign prostatic hyperplasia should<br />consider an alternative therapy as the efficacy of tadalafil 2.5 mg for the treatment of benign<br />prostatic hyperplasia has not been demonstrated.<br />Special Populations<br />Elderly Men<br />Dose adjustments are not required in elderly patients.<br />Men with Renal Impairment<br />Dose adjustments are not required in patients with mild to moderate renal impairment. For<br />patients with severe renal impairment, 10 mg is the maximum recommended dose.<br />Once-a-day dosing of 2.5 or 5 mg tadalafil both for the treatment of erectile dysfunction or benign<br />prostatic hyperplasia is not recommended in patients with severe renal impairment (see sections<br />4.4 and 5.2).<br />Men with Hepatic Impairment<br />For the treatment of erectile dysfunction using on-demand TANDO&reg; the recommended dose of<br />TANDO&reg; is 10 mg taken prior to anticipated sexual activity and with or without food. There is<br />limited clinical data on the safety of TANDO&reg; in patients with severe hepatic impairment (ChildPugh class C); if prescribed, a careful individual benefit/risk evaluation should be undertaken by<br />the prescribing physician. There are no available data about the administration of doses higher<br />than 10mg of tadalafil to patients with hepatic impairment.<br />Once-a-day dosing both for the treatment of erectile dysfunction and benign prostatic hyperplasia<br />has not been evaluated in patients with hepatic impairment; therefore, if prescribed, a careful<br />individual benefit/risk evaluation should be undertaken by the prescribing physician (see sections<br />4.4 and 5.2).<br />Men with Diabetes<br />Dose adjustments are not required in diabetic patients.<br />Paediatric population<br />There is no relevant use of TANDO&reg; in the paediatric population with regard to the treatment of<br />erectile dysfunction.<br />Method of administration<br />TANDO&reg; is available as 2.5, 5, 10, and 20 mg film-coated tablets for oral use<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
In clinical studies, tadalafil was shown to augment the hypotensive effects of nitrates. This is
thought to result from the combined effects of nitrates and tadalafil on the nitric oxide/cGMP
pathway. Therefore, administration of TANDO® to patients who are using any form of organic
nitrate is contraindicated (see section 4.5).
TANDO® must not be used in men with cardiac disease for whom sexual activity is inadvisable.
Physicians should consider the potential cardiac risk of sexual activity in patients with pre-existing
cardiovascular disease.
The following groups of patients with cardiovascular disease were not included in clinical trials
and the use of tadalafil is therefore contraindicated:
- patients with myocardial infarction within the last 90 days,
- patients with unstable angina or angina occurring during sexual intercourse,
- patients with New York Heart Association Class 2 or greater heart failure in the last 6 months,
- patients with uncontrolled arrhythmias, hypotension (<90/50 mm Hg), or uncontrolled
hypertension,
- patients with a stroke within the last 6 months.
TANDO® is contraindicated in patients who have loss of vision in one eye because of nonarteritic anterior ischaemic optic neuropathy (NAION), regardless of whether this episode was in
connection or not with previous PDE5 inhibitor exposure (see section 4.4).
The co-administration of PDE5 inhibitors, including tadalafil, with guanylate cyclase stimulators,
such as riociguat, is contraindicated as it may potentially lead to symptomatic hypotension (see
section 4.5)
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Before treatment with TANDO&reg;<br />A medical history and physical examination should be undertaken to diagnose erectile<br />dysfunction or benign prostatic hyperplasia and determine potential underlying causes, before<br />pharmacological treatment is considered.<br />Prior to initiating any treatment for erectile dysfunction, physicians should consider the<br />cardiovascular status of their patients, since there is a degree of cardiac risk associated with<br />sexual activity. Tadalafil has vasodilator properties, resulting in mild and transient decreases in<br />blood pressure (see section 5.1) and as such potentiates the hypotensive effect of nitrates (see<br />section 4.3).<br />The evaluation of erectile dysfunction should include a determination of potential underlying<br />causes and the identification of appropriate treatment following an appropriate medical<br />assessment. It is not known if TANDO&reg; is effective in patients who have undergone pelvic<br />surgery or radical non-nerve-sparing prostatectomy.<br />Tadalafil 5 mg - Prior to initiating treatment with tadalafil for benign prostatic hyperplasia patients<br />should be examined to rule out the presence of carcinoma of the prostate and carefully assessed<br />for cardiovascular conditions (see section 4.3).<br />Cardiovascular<br />Serious cardiovascular events, including myocardial infarction, sudden cardiac death, unstable<br />angina pectoris, ventricular arrhythmia, stroke, transient ischaemic attacks, chest pain,<br />palpitations and tachycardia, have been reported either post marketing and/or in clinical trials.<br />Most of the patients in whom these events have been reported had pre-existing cardiovascular<br />risk factors. However, it is not possible to definitively determine whether these events are related<br />directly to these risk factors, to TANDO&reg;, to sexual activity, or to a combination of these or other<br />factors.<br />Tadalafil 2.5 mg and 5 mg - In patients receiving concomitant antihypertensive medicinal<br />products, tadalafil may induce a blood pressure decrease. When initiating daily treatment with<br />tadalafil, appropriate clinical considerations should be given to a possible dose adjustment of the<br />antihypertensive therapy.<br />In patients who are taking alpha1 blockers, concomitant administration of TANDO&reg; may lead to<br />symptomatic hypotension in some patients (see section 4.5). The combination of tadalafil and<br />doxazosin is not recommended.<br />Vision<br />Visual defects and cases of NAION have been reported in connection with the intake of TANDO&reg;<br />and other PDE5 inhibitors. The patient should be advised that in case of sudden visual defect, he<br />should stop taking TANDO&reg; and consult a physician immediately (see section 4.3).<br />Renal and hepatic impairment (tadalafil 2.5 mg and 5 mg)<br />Due to increased tadalafil exposure (AUC), limited clinical experience and the lack of ability to<br />influence clearance by dialysis, once-a-day dosing of TANDO&reg; is not recommended in patients<br />with severe renal impairment.<br />There is limited clinical data on the safety of single-dose administration of TANDO&reg; in patients<br />with severe hepatic insufficiency (Child-Pugh Class C). Once-a-day administration has not been<br />evaluated in patients with hepatic insufficiency. If TANDO&reg; is prescribed, a careful individual<br />benefit/risk evaluation should be undertaken by the prescribing physician.<br />Hepatic impairment (tadalafil 10 mg and 20 mg)<br />There is limited clinical data on the safety of single-dose administration of TANDO&reg; in patients<br />with severe hepatic insufficiency (Child-Pugh Class C). If TANDO&reg; is prescribed, a careful<br />individual benefit/risk evaluation should be undertaken by the prescribing physician.<br />Priapism and anatomical deformation of the penis<br />Patients who experience erections lasting 4 hours or more should be instructed to seek<br />immediate medical assistance. If priapism is not treated immediately, penile tissue damage and<br />permanent loss of potency may result.<br />TANDO&reg;, should be used with caution in patients with anatomical deformation of the penis (such<br />as angulation, cavernosal fibrosis, or Peyronie&#39;s disease) or in patients who have conditions<br />which may predispose them to priapism (such as sickle cell anaemia, multiple myeloma or<br />leukaemia).<br />Use with CYP3A4 inhibitors<br />Caution should be exercised when prescribing TANDO&reg; to patients using potent CYP3A4<br />inhibitors (ritonavir, saquinavir, ketoconazole, itraconazole, and erythromycin), as increased<br />tadalafil exposure (AUC) has been observed if the medicinal products are combined (see section<br />4.5).<br />TANDO&reg; and other treatments for erectile dysfunction<br />The safety and efficacy of combinations of TANDO&reg; and other PDE5 inhibitors or other<br />treatments for erectile dysfunction have not been studied. The patients should be informed not to<br />take TANDO&reg; in such combinations.<br />Lactose<br />TANDO&reg; contains lactose. Patients with rare hereditary problems of galactose intolerance, the<br />Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicinal<br />product<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Interaction studies were conducted with 10 mg and/or 20 mg tadalafil, as indicated below. With<br />regard to those interaction studies where only the 10 mg tadalafil dose was used, clinically<br />relevant interactions at higher doses cannot be completely ruled out.<br />Effects of Other Substances on Tadalafil<br />Cytochrome P450 inhibitors<br />Tadalafil is principally metabolised by CYP3A4. A selective inhibitor of CYP3A4, ketoconazole<br />(200 mg daily), increased tadalafil (10 mg) exposure (AUC) 2-fold and Cmax by 15%, relative to<br />the AUC and Cmax values for tadalafil alone. Ketoconazole (400 mg daily) increased tadalafil (20<br />mg) exposure (AUC) 4-fold and Cmax by 22%. Ritonavir, a protease inhibitor (200 mg twice daily),<br />which is an inhibitor of CYP3A4, CYP2C9, CYP2C19, and CYP2D6, increased tadalafil (20 mg)<br />exposure (AUC) 2-fold with no change in Cmax. Although specific interactions have not been<br />studied, other protease inhibitors, such as saquinavir, and other CYP3A4 inhibitors, such as<br />erythromycin, clarithromycin, itraconazole, and grapefruit juice, should be co-administered with<br />caution, as they would be expected to increase plasma concentrations of tadalafil (see section<br />4.4). Consequently, the incidence of the adverse reactions listed in section 4.8 might be<br />increased.<br />Transporters<br />The role of transporters (for example, p-glycoprotein) in the disposition of tadalafil is not known.<br />Therefore, there is the potential of drug interactions mediated by inhibition of transporters.<br />Cytochrome P450 inducers<br />A CYP3A4 inducer, rifampicin, reduced tadalafil AUC by 88%, relative to the AUC values for<br />tadalafil alone (10 mg). This reduced exposure can be anticipated to decrease the efficacy of<br />tadalafil; the magnitude of decreased efficacy is unknown. Other inducers of CYP3A4, such as<br />phenobarbital, phenytoin, and carbamazepine, may also decrease plasma concentrations of<br />tadalafil.<br />Effects of Tadalafil on Other Medicinal Products<br />Nitrates<br />In clinical studies, tadalafil (5, 10 and 20 mg) was shown to augment the hypotensive effects of<br />nitrates. Therefore, administration of TANDO&reg; to patients who are using any form of organic<br />nitrate is contraindicated (see section 4.3). Based on the results of a clinical study in which 150<br />subjects receiving daily doses of tadalafil 20 mg for 7 days and 0.4 mg sublingual nitroglycerin at<br />various times, this interaction lasted for more than 24 hours and was no longer detectable when<br />48 hours had elapsed after the last tadalafil dose. Thus, in a patient prescribed any dose of<br />TANDO&reg; (2.5 mg- 20 mg), where nitrate administration is deemed medically necessary in a lifethreatening situation, at least 48 hours should have elapsed after the last dose of TANDO&reg;<br />before nitrate administration is considered. In such circumstances, nitrates should only be<br />administered under close medical supervision with appropriate haemodynamic monitoring.<br />Anti-hypertensives (including calcium channel blockers)<br />The co-administration of doxazosin (4 and 8 mg daily) and tadalafil (5 mg daily dose and 20 mg<br />as a single dose) increases the blood pressure-lowering effect of this alpha-blocker in a<br />significant manner. This effect lasts at least twelve hours and may be symptomatic, including<br />syncope. Therefore, this combination is not recommended (see section 4.4).<br />In interaction studies performed in a limited number of healthy volunteers, these effects were not<br />reported with alfuzosin or tamsulosin. However, caution should be exercised when using tadalafil<br />in patients treated with any alpha-blockers, and notably in the elderly. Treatments should be<br />initiated at minimal dosage and progressively adjusted.<br />In clinical pharmacology studies, the potential for tadalafil to augment the hypotensive effects of<br />antihypertensive medicinal products was examined. Major classes of antihypertensive medicinal<br />products were studied, including calcium-channel blockers (amlodipine), angiotensin converting<br />enzyme (ACE) inhibitors (enalapril), beta-adrenergic receptor blockers (metoprolol), thiazide<br />diuretics (bendrofluazide), and angiotensin II receptor blockers (various types and doses, alone or<br />in combination with thiazides, calcium-channel blockers, beta-blockers, and/or alpha-blockers).<br />Tadalafil (10 mg, except for studies with angiotensin II receptor blockers and amlodipine in which<br />a 20 mg dose was applied) had no clinically significant interaction with any of these classes. In<br />another clinical pharmacology study, tadalafil (20 mg) was studied in combination with up to 4<br />classes of antihypertensives. In subjects taking multiple antihypertensives, the ambulatory-bloodpressure changes appeared to relate to the degree of blood pressure control. In this regard, study<br />subjects whose blood pressure was well controlled, the reduction was minimal and similar to that<br />seen in healthy subjects. In study subjects whose blood pressure was not controlled, the<br />reduction was greater, although this reduction was not associated with hypotensive symptoms in<br />the majority of subjects. In patients receiving concomitant antihypertensive medicinal products,<br />tadalafil 20 mg may induce a blood pressure decrease, which (with the exception of alphablockers - see above) is, in general, minor and not likely to be clinically relevant. Analysis of<br />Phase 3 clinical trial data showed no difference in adverse events in patients taking tadalafil with<br />or without antihypertensive medicinal products. However, appropriate clinical advice should be<br />given to patients regarding a possible decrease in blood pressure when they are treated with<br />antihypertensive medicinal products.<br />Riociguat<br />Preclinical studies showed an additive systemic blood pressure lowering effect when PDE5<br />inhibitors were combined with riociguat. In clinical studies, riociguat has been shown to augment<br />the hypotensive effects of PDE5 inhibitors. There was no evidence of favourable clinical effect of<br />the combination in the population studied. Concomitant use of riociguat with PDE5 inhibitors,<br />including tadalafil, is contraindicated (see section 4.3).<br />5- alpha reductase inhibitors<br />In a clinical trial that compared tadalafil 5 mg coadministered with finasteride 5 mg to placebo<br />plus finasteride 5 mg in the relief of BPH symptoms, no new adverse reactions were identified.<br />However, as a formal drug-drug interaction study evaluating the effects of tadalafil and 5-alpha<br />reductase inhibitors (5-ARIs) has not been performed, caution should be exercised when tadalafil<br />is co-administered with 5-ARIs.<br />CYP1A2 substrates (e.g. theophylline)<br />When tadalafil 10 mg was administered with theophylline (a non-selective phosphodiesterase<br />inhibitor) in a clinical pharmacology study, there was no pharmacokinetic interaction. The only<br />pharmacodynamic effect was a small (3.5 bpm) increase in heart rate. Although this effect is<br />minor and was of no clinical significance in this study, it should be considered when coadministering these medicinal products.<br />Ethinylestradiol and terbutaline<br />Tadalafil has been demonstrated to produce an increase in the oral bioavailability of<br />ethinylestradiol; a similar increase may be expected with oral administration of terbutaline,<br />although the clinical consequence of this is uncertain.<br />Alcohol<br />Alcohol concentrations (mean maximum blood concentration 0.08%) were not affected by coadministration with tadalafil (10 mg or 20 mg). In addition, no changes in tadalafil concentrations<br />were seen 3 hours after co-administration with alcohol. Alcohol was administered in a manner to<br />maximise the rate of alcohol absorption (overnight fast with no food until 2 hours after alcohol).<br />Tadalafil (20 mg) did not augment the mean blood pressure decrease produced by alcohol (0.7<br />g/kg or approximately 180 ml of 40% alcohol [vodka] in an 80 kg male) but, in some subjects,<br />postural dizziness and orthostatic hypotension were observed. When tadalafil was administered<br />with lower doses of alcohol (0.6 g/kg), hypotension was not observed and dizziness occurred with<br />similar frequency to alcohol alone. The effect of alcohol on cognitive function was not augmented<br />by tadalafil (10 mg).<br />Cytochrome P450 metabolised medicinal products<br />Tadalafil is not expected to cause clinically significant inhibition or induction of the clearance of<br />medicinal products metabolised by CYP450 isoforms. Studies have confirmed that tadalafil does<br />not inhibit or induce CYP450 isoforms, including CYP3A4, CYP1A2, CYP2D6, CYP2E1, CYP2C9<br />and CYP2C19.<br />CYP2C9 substrates (e.g. R-warfarin)<br />Tadalafil (10 mg and 20 mg) had no clinically significant effect on exposure (AUC) to S-warfarin<br />or R-warfarin (CYP2C9 substrate), nor did tadalafil affect changes in prothrombin time induced by<br />warfarin.<br />Aspirin<br />Tadalafil (10 mg and 20 mg) did not potentiate the increase in bleeding time caused by<br />acetylsalicylic acid.<br />Antidiabetic medicinal products<br />Specific interaction studies with antidiabetic medicinal products were not conducted<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>TANDO&reg; is not indicated for use by women.<br />Pregnancy Category: B<br />Pregnancy<br />There are limited data from the use of tadalafil in pregnant women. Animal studies do not indicate<br />direct or indirect harmful effects with respect to pregnancy, embryonal/foetal development,<br />parturition or postnatal development (see section 5.3). As a precautionary measure, it is<br />preferable to avoid the use of TANDO&reg; during pregnancy.<br />Breastfeeding<br />Available pharmacodynamic/toxicological data in animals have shown excretion of tadalafil in<br />milk. A risk to the suckling child cannot be excluded. TANDO&reg; should not be used during breast<br />feeding.<br />Fertility<br />Effects were seen in dogs that might indicate impairment of fertility. Two subsequent clinical<br />studies suggest that this effect is unlikely in humans, although a decrease in sperm concentration<br />was seen in some men (see sections 5.1 and 5.3)<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>TANDO&reg; has negligible influence on the ability to drive or use machines. Although the frequency<br />of reports of dizziness in placebo and tadalafil arms in clinical trials was similar, patients should<br />be aware of how they react to TANDO&reg; before driving or using machines<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>a. Summary of the safety profile<br />The most commonly reported adverse reactions in patients taking TANDO&reg; for the treatment of<br />erectile dysfunction or benign prostatic hyperplasia were headache, dyspepsia, back pain and<br />myalgia, in which the incidences increase with increasing dose of TANDO&reg;. The adverse<br />reactions reported were transient, and generally mild or moderate. The majority of headaches<br />reported with TANDO&reg; once-a-day dosing are experienced within the first 10 to 30 days of<br />starting treatment.<br />b. Tabulated summary of adverse reactions<br />The table below lists the adverse reactions observed from spontaneous reporting and in placebocontrolled clinical trials (comprising a total of 8022 patients on TANDO&reg; and 4422 patients on<br />placebo) for on-demand and once-a-day treatment of erectile dysfunction and the once-a-day<br />treatment of benign prostatic hyperplasia.<br />Frequency convention: Very common (&ge;1/10), Common (&ge;1/100 to &lt;1/10), Uncommon (&ge;1/1,000<br />to &lt;1/100), Rare (&ge;1/10,000 to &lt;1/1,000), Very Rare (&lt;1/10,000) and Not known (cannot be<br />estimated from the available data)<br /><img src="data:image/png;base64,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" alt="" width="560" height="66" vspace="0" hspace="0" border="0" style="width:560px;height:66px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></p><p><img src="data:image/png;base64,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" alt="" width="553" height="660" vspace="0" hspace="0" border="0" style="width:553px;height:660px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></p><p><img src="data:image/png;base64,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" alt="" width="527" height="31" vspace="0" hspace="0" border="0" style="width:527px;height:31px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></p><p>c. Description of selected adverse reactions<br />A slightly higher incidence of ECG abnormalities, primarily sinus bradycardia, has been reported<br />in patients treated with tadalafil once a day as compared with placebo. Most of these ECG<br />abnormalities were not associated with adverse reactions.<br />d. Paediatric population<br />There is no relevant use of TANDO&reg; in the paediatric population with regard to the treatment of<br />erectile dysfunction.<br />e. Other special populations<br />Data in patients over 65 years of age receiving tadalafil in clinical trials, either for the treatment of<br />erectile dysfunction or the treatment of benign prostatic hyperplasia, are limited. In clinical trials<br />with tadalafil taken on demand for the treatment of erectile dysfunction, diarrhoea was reported<br />more frequently in patients over 65 years of age. In clinical trials with tadalafil 5 mg taken once a<br />day for the treatment of benign prostatic hyperplasia, dizziness and diarrhoea were reported more<br />frequently in patients over 75 years of age.<br />Elderly Men<br />Dose adjustments are not required in elderly patients.<br />Men with Renal Impairment<br />Dose adjustments are not required in patients with mild to moderate renal impairment. For<br />patients with severe renal impairment, 10 mg is the maximum recommended dose.<br />Once-a-day dosing of 2.5 or 5 mg tadalafil both for the treatment of erectile dysfunction or benign<br />prostatic hyperplasia is not recommended in patients with severe renal impairment (see sections<br />4.4 and 5.2).<br />Men with Hepatic Impairment<br />For the treatment of erectile dysfunction using on-demand TANDO&reg; the recommended dose of<br />TANDO&reg; is 10 mg taken prior to anticipated sexual activity and with or without food. There is<br />limited clinical data on the safety of TANDO&reg; in patients with severe hepatic impairment (ChildPugh class C); if prescribed, a careful individual benefit/risk evaluation should be undertaken by<br />the prescribing physician. There are no available data about the administration of doses higher<br />than 10mg of tadalafil to patients with hepatic impairment.<br />Once-a-day dosing both for the treatment of erectile dysfunction and benign prostatic hyperplasia<br />has not been evaluated in patients with hepatic impairment; therefore, if prescribed, a careful<br />individual benefit/risk evaluation should be undertaken by the prescribing physician (see sections<br />4.4 and 5.2).<br />Men with Diabetes<br />Dose adjustments are not required in diabetic patients<br /><img src="data:image/png;base64,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" alt="" width="536" height="197" vspace="0" hspace="0" border="0" style="width:536px;height:197px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></p><p><img src="data:image/png;base64,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" alt="" width="515" height="45" vspace="0" hspace="0" border="0" style="width:515px;height:45px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Single doses of up to 500 mg have been given to healthy subjects, and multiple daily doses up to<br />100 mg have been given to patients. Adverse events were similar to those seen at lower doses.<br />In cases of overdose, standard supportive measures should be adopted, as required.<br />Haemodialysis contributes negligibly to tadalafil elimination<br />&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Urologicals, Drugs used in erectile dysfunction. ATC code:<br />G04BE08.<br />Mechanism of action<br />Tadalafil is a selective, reversible inhibitor of cyclic guanosine monophosphate (cGMP)-specific<br />phosphodiesterase type 5 (PDE5). When sexual stimulation causes the local release of nitric<br />oxide, inhibition of PDE5 by tadalafil produces increased levels of cGMP in the corpus<br />cavernosum. This results in smooth muscle relaxation and inflow of blood into the penile tissues,<br />thereby producing an erection. Tadalafil has no effect in the treatment of erectile dysfunction in<br />the absence of sexual stimulation.<br />Tadalafil 5 mg - The effect of PDE5 inhibition on cGMP concentration in the corpus cavernosum<br />is also observed in the smooth muscle of the prostate, the bladder and their vascular supply. The<br />resulting vascular relaxation increases blood perfusion which may be the mechanism by which<br />symptoms of benign prostatic hyperplasia are reduced. These vascular effects may be<br />complemented by inhibition of bladder afferent nerve activity and smooth muscle relaxation of the<br />prostate and bladder.<br />Pharmacodynamic effects<br />Studies in vitro have shown that tadalafil is a selective inhibitor of PDE5. PDE5 is an enzyme<br />found in corpus cavernosum smooth muscle, vascular and visceral smooth muscle, skeletal<br />muscle, platelets, kidney, lung, and cerebellum. The effect of tadalafil is more potent on PDE5<br />than on other phosphodiesterases. Tadalafil is &gt;10,000-fold more potent for PDE5 than for PDE1,<br />PDE2, and PDE4 enzymes which are found in the heart, brain, blood vessels, liver, and other<br />organs. Tadalafil is &gt;10,000-fold more potent for PDE5 than for PDE3, an enzyme found in the<br />heart and blood vessels. This selectivity for PDE5 over PDE3 is important because PDE3 is an<br />enzyme involved in cardiac contractility. Additionally, tadalafil is approximately 700-fold more<br />potent for PDE5 than for PDE6, an enzyme which is found in the retina and is responsible for<br />phototransduction. Tadalafil is also &gt;10,000-fold more potent for PDE5 than for PDE7 through<br />PDE10.<br />Clinical efficacy and safety<br />Tadalafil administered to healthy subjects produced no significant difference compared to placebo<br />in supine systolic and diastolic blood pressure (mean maximal decrease of 1.6/0.8mmHg,<br />respectively), in standing systolic and diastolic blood pressure (mean maximal decrease of<br />0.2/4.6mmHg, respectively), and no significant change in heart rate.<br />In a study to assess the effects of tadalafil on vision, no impairment of colour discrimination<br />(blue/green) was detected using the Farnsworth-Munsell 100-hue test. This finding is consistent<br />with the low affinity of tadalafil for PDE6 compared to PDE5. Across all clinical studies, reports of<br />changes in colour vision were rare (&lt;0.1%).<br />Three studies were conducted in men to assess the potential effect on spermatogenesis of<br />TANDO&reg; 10mg (one 6-month study) and 20mg (one 6-month and one 9-month study)<br />administered daily. In two of these studies decreases were observed in sperm count and<br />concentration related to tadalafil treatment of unlikely clinical relevance. These effects were not<br />associated with changes in other parameters, such as motility, morphology, and FSH.<br />Erectile dysfunction<br />Three clinical studies were conducted in 1054 patients in an at-home setting to define the period<br />of responsiveness to TANDO&reg; on demand. Tadalafil demonstrated statistically significant<br />improvement in erectile function and the ability to have successful sexual intercourse up to 36<br />hours following dosing, as well as patients&#39; ability to attain and maintain erections for successful<br />intercourse compared to placebo as early as 16 minutes following dosing.<br />In a 12-week study performed in 186 patients (142 tadalafil, 44 placebo) with erectile dysfunction<br />secondary to spinal cord injury, tadalafil significantly improved the erectile function leading to a<br />mean per-subject proportion of successful attempts in patients treated with tadalafil 10 or 20 mg<br />(flexible-dose, on demand) of 48% as compared to 17% with placebo.<br />Tadalafil at doses of 2 to 100mg has been evaluated in 16 clinical studies involving 3250 patients,<br />including patients with erectile dysfunction of various severities (mild, moderate, severe),<br />etiologies, ages (range 21-86 years), and ethnicities. Most patients reported erectile dysfunction<br />of at least 1 year in duration. In the primary efficacy studies of general populations, 81% of<br />patients reported that TANDO&reg; improved their erections as compared to 35% with placebo. Also,<br />patients with erectile dysfunction in all severity categories reported improved erections whilst<br />taking TANDO&reg; (86%, 83%, and 72% for mild, moderate, and severe, respectively, as compared<br />to 45%, 42%, and 19% with placebo). In the primary efficacy studies, 75% of intercourse attempts<br />were successful in TANDO&reg;-treated patients as compared to 32% with placebo.<br />For once-a-day evaluation of tadalafil at doses of 2.5, 5, and 10 mg 3 clinical studies were initially<br />conducted involving 853 patients of various ages (range 21-82 years) and ethnicities, with erectile<br />dysfunction of various severities (mild, moderate, severe) and etiologies. In the two primary<br />efficacy studies of general populations, the mean per-subject proportion of successful intercourse<br />attempts were 57 and 67% on TANDO&reg; 5mg, 50% on TANDO&reg; 2.5mg as compared to 31 and<br />37% with placebo. In the study in patients with erectile dysfunction secondary to diabetes, the<br />mean per-subject proportion of successful attempts were 41 and 46% on TANDO&reg; 5mg and<br />2.5mg, respectively, as compared to 28% with placebo. Most patients in these three studies were<br />responders to previous on-demand treatment with PDE5 inhibitors. In a subsequent study, 217<br />patients who were treatment-naive to PDE5 inhibitors were randomised to TANDO&reg; 5mg once a<br />day vs. placebo. The mean per-subject proportion of successful sexual intercourse attempts was<br />68% for TANDO&reg; patients compared to 52% for patients on placebo.<br />Benign prostatic hyperplasia<br />TANDO&reg; was studied in 4 clinical studies of 12 weeks duration enrolling over 1500 patients with<br />signs and symptoms of benign prostatic hyperplasia. The improvement in the total international<br />prostate symptom score with TANDO&reg; 5mg in the four studies were -4.8, -5.6, -6.1 and -6.3<br />compared to -2.2, -3.6, -3.8 and -4.2 with placebo. The improvements in total international<br />prostate symptom score occurred as early as 1 week. In one of the studies, which also included<br />tamsulosin 0.4 mg as an active comparator, the improvement in total international prostate<br />symptom score with TANDO&reg; 5mg, tamsulosin and placebo were -6.3, -5.7 and -4.2 respectively.<br />One of these studies assessed improvements in erectile dysfunction and signs and symptoms of<br />benign prostatic hyperplasia in patients with both conditions. The improvements in the erectile<br />function domain of the international index of erectile function and the total international prostate<br />symptom score in this study were 6.5 and -6.1 with TANDO&reg; 5 mg compared to 1.8 and -3.8 with<br />placebo, respectively. The mean per-subject proportion of successful sexual intercourse attempts<br />was 71.9% with TANDO&reg; 5 mg compared to 48.3% with placebo.<br />The maintenance of the effect was evaluated in an open-label extension to one of the studies,<br />which showed that the improvement in total international prostate symptom score seen at 12<br />weeks was maintained for up to 1 additional year of treatment with TANDO&reg; 5mg.<br />Paediatric population<br />The European Medicines Agency has waived the obligation to submit the results of studies in all<br />subsets of the paediatric population in the treatment of the erectile dysfunction. See section 4.2<br />for information on paediatric use<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Absorption<br />Tadalafil is readily absorbed after oral administration and the mean maximum observed plasma<br />concentration (Cmax) is achieved at a median time of 2 hours after dosing. Absolute bioavailability<br />of tadalafil following oral dosing has not been determined.<br />The rate and extent of absorption of tadalafil are not influenced by food, thus TANDO&reg; may be<br />taken with or without food. The time of dosing (morning versus evening) had no clinically relevant<br />effects on the rate and extent of absorption.<br />Distribution<br />The mean volume of distribution is approximately 63 l, indicating that tadalafil is distributed into<br />tissues. At therapeutic concentrations, 94% of tadalafil in plasma is bound to proteins. Protein<br />binding is not affected by impaired renal function.<br />Less than 0.0005% of the administered dose appeared in the semen of healthy subjects.<br />Biotransformation<br />Tadalafil is predominantly metabolised by the cytochrome P450 (CYP) 3A4 isoform. The major<br />circulating metabolite is the methylcatechol glucuronide. This metabolite is at least 13,000-fold<br />less potent than tadalafil for PDE5. Consequently, it is not expected to be clinically active at<br />observed metabolite concentrations.<br />Elimination<br />The mean oral clearance for tadalafil is 2.5 l/h and the mean half-life is 17.5 hours in healthy<br />subjects.<br />Tadalafil is excreted predominantly as inactive metabolites, mainly in the faeces (approximately<br />61% of the dose) and to a lesser extent in the urine (approximately 36% of the dose).<br />Linearity/Non-Linearity<br />Tadalafil pharmacokinetics in healthy subjects are linear with respect to time and dose. Over a<br />dose range of 2.5 to 20 mg, exposure (AUC) increases proportionally with dose. Steady-state<br />plasma concentrations are attained within 5 days of once daily dosing.<br />Pharmacokinetics determined with a population approach in patients with erectile dysfunction are<br />similar to pharmacokinetics in subjects without erectile dysfunction.<br />Special Populations<br />Elderly<br />Healthy elderly subjects (65 years or over) had a lower oral clearance of tadalafil, resulting in<br />25% higher exposure (AUC) relative to healthy subjects aged 19 to 45 years. This effect of age is<br />not clinically significant and does not warrant a dose adjustment.<br />Renal Insufficiency<br />In clinical pharmacology studies using single dose tadalafil (5 to 20mg), tadalafil exposure (AUC)<br />approximately doubled in subjects with mild (creatinine clearance 51 to 80 ml/min) or moderate<br />(creatinine clearance 31 to 50 ml/min) renal impairment and in subjects with end-stage renal<br />disease on dialysis. In haemodialysis patients, Cmax was 41% higher than that observed in healthy<br />subjects. Haemodialysis contributes negligibly to tadalafil elimination.<br />Hepatic Insufficiency<br />Tadalafil exposure (AUC) in subjects with mild and moderate hepatic impairment (Child-Pugh<br />class A and B) is comparable to exposure in healthy subjects when a dose of 10 mg is<br />administered. There is limited clinical data on the safety of TANDO&reg; in patients with severe<br />hepatic insufficiency (Child-Pugh class C). If TANDO&reg; is prescribed, a careful individual<br />benefit/risk evaluation should be undertaken by the prescribing physician. There are no available<br />data about the administration of once-a-day dosing of tadalafil to patients with hepatic<br />impairment. If TANDO&reg; is prescribed once-a-day, a careful individual benefit/risk evaluation<br />should be undertaken by the prescribing physician. There are no available data about the<br />administration of doses higher than 10 mg of tadalafil to patients with hepatic impairment.<br />Patients with Diabetes<br />Tadalafil exposure (AUC) in patients with diabetes was approximately 19% lower than the AUC<br />value for healthy subjects. This difference in exposure does not warrant a dose adjustment<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data reveal no special hazard for humans based on conventional studies of safety<br />pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential, and toxicity to<br />reproduction.<br />There was no evidence of teratogenicity, embryotoxicity, or foetotoxicity in rats or mice that<br />received up to 1000 mg/kg/day tadalafil. In a rat prenatal and postnatal development study, the<br />no observed effect dose was 30 mg/kg/day. In the pregnant rat the AUC for calculated free drug<br />at this dose was approximately 18-times the human AUC at a 20 mg dose.<br />There was no impairment of fertility in male and female rats. In dogs given tadalafil daily for 6 to<br />12 months at doses of 25 mg/kg/day (resulting in at least a 3-fold greater exposure [range 3.7-<br />18.6] than seen in humans given a single 20 mg dose) and above, there was regression of the<br />seminiferous tubular epithelium that resulted in a decrease in spermatogenesis in some dogs.<br />See also section 5.1<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Lactose Monohydrate<br />Low Substituted Hydroxypropyl Cellulose<br />Croscarmellose Sodium<br />Sodium Lauryl Sulfate<br />Microcrystalline Cellulose,<br />Magnesium stearate<br />Opadry Yellow 02A22352<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C.<br />This medicinal product does not require any special storage conditions<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>TANDO&reg; 5 is supplied as blister (PVC/PE/PVDC/ALU blister). Packs with 10 and 30 film coated<br />tablets.<br />TANDO&reg; 10 mg are supplied as blister (PVC/PE/PVDC/ALU blister). Packs with 10 film coated<br />tablets.<br />TANDO&reg; 20 mg is supplied as blister (ALU/ALU blister). Packs with 4 film coated tablets<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused medicinal product or waste material should be disposed of in accordance with local<br />requirements<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                SAJA Pharmaceuticals
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                October/2016
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>